{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-21-006545","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2021-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.061419+00:00","generated_at":"2026-06-29T02:48:48.302904+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"BioCryst appoints former FDA deputy center director Dr. Amy McKee to board of directors","bullets":["Board expanded from 10 to 11 members; Dr. McKee elected effective September 20, 2021.","Dr. McKee served as Deputy Center Director for FDA's Oncology Center of Excellence and is now VP at Parexel.","Dr. McKee to serve on Science Committee; receives initial grant of 53,333 stock options plus annual grants of 40,000 options.","Appointment brings regulatory expertise as BioCryst advances BCX9930 into pivotal trials for PNH and other complement diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-21-006545","json":"https://secwatch.observer/filing/0001171843-21-006545.json","markdown":"https://secwatch.observer/filing/0001171843-21-006545.md","text":"https://secwatch.observer/filing/0001171843-21-006545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184321006545/0001171843-21-006545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184321006545/f8k_092021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T02:48:48.302904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee318681fe","claim":"Amy McKee was elected as Director at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"elected Amy McKee, M.D. to fill the vacancy created by the enlargement of the Board, effective September 20, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184321006545/0001171843-21-006545-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}